Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Valganciclovir
Drug ID BADD_D02326
Description Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases.
Indications and Usage Valganciclovir is an antiviral medication used for the treatment of cytomegalovirus infections.
Marketing Status approved; investigational
ATC Code J05AB14
DrugBank ID DB01610
KEGG ID D02495
MeSH ID D000077562
PubChem ID 135413535
TTD Drug ID D06GWF
NDC Product Code 69097-277; 31722-832; 50268-787; 60429-846; 70069-810; 71921-210; 27241-158; 55111-762; 61269-480; 0004-0038; 70010-051; 0904-6796; 63739-076; 68084-965; 71151-003
UNII GCU97FKN3R
Synonyms Valganciclovir | Ganciclovir L-valyl Ester | Ganciclovir L valyl Ester | Valcyt | Valganciclovir Hydrochloride | Valcyte
Chemical Information
Molecular Formula C14H22N6O5
CAS Registry Number 175865-60-8
SMILES CC(C)C(C(=O)OCC(CO)OCN1C=NC2=C1N=C(NC2=O)N)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cytomegalovirus syndrome11.05.01.005--Not Available
Procedural complication12.02.05.005--
Post procedural complication12.02.05.018--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Angiopathy24.03.02.007--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Cardiac disorder02.11.01.003--Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Infestation23.11.01.002; 11.09.01.001--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction21.03.01.007; 19.08.04.001--
Ill-defined disorder08.01.03.049--Not Available
Inner ear disorder04.04.02.002--Not Available
Blood disorder01.05.01.004--Not Available
Psychotic disorder19.03.01.002--
Hepatobiliary disease09.01.08.003--Not Available
Renal impairment20.01.03.010--Not Available
Device related infection11.01.08.018; 08.07.01.005--
Procedural pain12.02.05.007; 08.01.08.009--Not Available
Bone marrow failure01.03.03.005--
Oropharyngeal discomfort22.12.03.015; 07.05.05.008--Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.004--
Pneumocystis jirovecii pneumonia11.03.07.005; 22.07.08.009--Not Available
Candida infection11.03.03.021--
Systemic infection11.01.08.050--Not Available
Anal incontinence17.05.01.021; 07.01.06.029--
Attention deficit hyperactivity disorder19.21.04.004--Not Available
The 7th Page    First    Pre   7 8    Next   Last    Total 8 Pages